Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RAPP
RAPP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RAPP News
Rapport Therapeutics Q1 Financial Results Analysis
May 07 2026
seekingalpha
Third Rock Ventures Sells Shares in Rapport Therapeutics
Apr 27 2026
Fool
Rapport Therapeutics' RAP-219 Shows Significant Seizure Reduction in Epilepsy Patients
Apr 22 2026
NASDAQ.COM
Form 144: Rapport Therapeutics (RAPP.US) 10% Stakeholder Plans to Sell $17.18 Million in Common Shares
Apr 17 2026
moomoo
Rapport Therapeutics Reports Q4 Earnings Miss
Mar 10 2026
seekingalpha
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results
Mar 09 2026
Benzinga
RAPPORT THERAPEUTICS STOCK RISES 5% AFTER AWARDING CHINA RIGHTS FOR EPILEPSY MEDICATION
Mar 09 2026
moomoo
Rapport Partners with Tenacia for RAP-219 Development in Greater China
Mar 09 2026
Yahoo Finance
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials
Jan 08 2026
NASDAQ.COM
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $94.82 Million
Dec 22 2025
Fool
Cormorant Increases Stake in Rapport Therapeutics by 251,600 Shares Worth $61.38 Million
Dec 22 2025
NASDAQ.COM
Rapport Therapeutics, Inc. (RAPP) Sees a 9.03% Increase Over the Past Week: Key Insights to Consider
Dec 08 2025
NASDAQ.COM
Valuation Assessment of Rapport Therapeutics (RAPP) Following 60% Increase in Share Price This Year
Dec 07 2025
Yahoo Finance
RAP-219 Phase 2a Seizure Results and Upcoming Pivotal Trials Could Influence Investment Decisions in Rapport Therapeutics (RAPP)
Dec 06 2025
Yahoo Finance
Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency
Dec 05 2025
Globenewswire
Rapport Therapeutics Reports RAP-219 Clinical Data, Significantly Reducing Seizure Frequency
Dec 05 2025
Newsfilter
Show More News
